Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMRA NASDAQ:DYAI NASDAQ:NEUP NASDAQ:PLRZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRABiomerica$2.11-3.2%$2.23$1.87▼$4.60$6.74M0.3120,471 shs9,969 shsDYAIDyadic International$0.70+1.6%$0.79$0.65▼$1.35$25.13M1.17584,369 shs142,534 shsNEUPNeuphoria Therapeutics$4.70-3.9%$4.87$3.64▼$21.40$26.43M0.7248,944 shs76,497 shsPLRZPolyrizon$13.46-4.5%$13.79$2.88▼$18.20$26.37M-1.938,419 shs18,393 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRABiomerica-7.63%-11.74%-0.46%+7.39%-35.69%DYAIDyadic International-11.12%-8.65%-12.70%-16.30%-32.38%NEUPNeuphoria Therapeutics-7.74%-10.44%-6.32%+5.39%-30.24%PLRZPolyrizon-8.57%-12.32%-11.94%+4.68%+205.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRABiomerica$2.11-3.2%$2.23$1.87▼$4.60$6.74M0.3120,471 shs9,969 shsDYAIDyadic International$0.70+1.6%$0.79$0.65▼$1.35$25.13M1.17584,369 shs142,534 shsNEUPNeuphoria Therapeutics$4.70-3.9%$4.87$3.64▼$21.40$26.43M0.7248,944 shs76,497 shsPLRZPolyrizon$13.46-4.5%$13.79$2.88▼$18.20$26.37M-1.938,419 shs18,393 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRABiomerica-7.63%-11.74%-0.46%+7.39%-35.69%DYAIDyadic International-11.12%-8.65%-12.70%-16.30%-32.38%NEUPNeuphoria Therapeutics-7.74%-10.44%-6.32%+5.39%-30.24%PLRZPolyrizon-8.57%-12.32%-11.94%+4.68%+205.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMRABiomerica 1.00Sell$9.00326.54% UpsideDYAIDyadic International 2.33Hold$3.00327.96% UpsideNEUPNeuphoria Therapeutics 2.00Hold$21.00346.81% UpsidePLRZPolyrizon 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest BMRA, PLRZ, NEUP, and DYAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026NEUPNeuphoria Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/21/2026BMRABiomerica Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/21/2026PLRZPolyrizon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026NEUPNeuphoria Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/5/2026BMRABiomerica Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMkt Outperform$9.005/4/2026PLRZPolyrizon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026DYAIDyadic International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMRABiomerica$5.31M1.23N/AN/A$1.61 per share1.31DYAIDyadic International$3.09M8.27N/AN/A$0.03 per share23.37NEUPNeuphoria Therapeutics$15.65M1.62$0.15 per share31.38$10.11 per share0.46PLRZPolyrizonN/AN/AN/AN/A$13.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMRABiomerica-$4.97M-$0.89N/AN/AN/A-96.49%-98.14%-70.42%N/ADYAIDyadic International-$7.36M-$0.23N/AN/AN/A-192.40%-1,005.45%-77.64%8/12/2026 (Estimated)NEUPNeuphoria Therapeutics-$370K-$11.06N/AN/AN/AN/A-76.93%-54.76%N/APLRZPolyrizon-$3.34MN/AN/AN/AN/AN/AN/AN/AN/ALatest BMRA, PLRZ, NEUP, and DYAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q3 2026NEUPNeuphoria Therapeutics-$0.56-$0.09+$0.47-$0.09N/AN/A5/13/2026Q1 2026DYAIDyadic International-$0.04-$0.05-$0.01-$0.05$0.90 million$1.11 million4/13/2026Q3 2026BMRABiomerica-$1.20-$0.44+$0.76-$0.44$3.63 million$0.99 million3/25/2026Q4 2025DYAIDyadic International-$0.03-$0.06-$0.03-$0.06$1.34 million$0.57 million3/25/2026Q4 2025PLRZPolyrizonN/A$2.81N/A-$2.81N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBMRABiomericaN/AN/AN/AN/AN/ADYAIDyadic InternationalN/AN/AN/AN/AN/ANEUPNeuphoria TherapeuticsN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMRABiomericaN/A2.641.59DYAIDyadic International4.082.422.42NEUPNeuphoria TherapeuticsN/A14.3114.31PLRZPolyrizonN/A29.0329.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMRABiomerica22.28%DYAIDyadic International27.95%NEUPNeuphoria Therapeutics15.90%PLRZPolyrizonN/AInsider OwnershipCompanyInsider OwnershipBMRABiomerica18.00%DYAIDyadic International20.90%NEUPNeuphoria Therapeutics1.50%PLRZPolyrizonN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMRABiomerica603.09 million2.53 millionNo DataDYAIDyadic International736.44 million28.82 millionOptionableNEUPNeuphoria TherapeuticsN/A5.40 million5.32 millionN/APLRZPolyrizonN/A1.87 millionN/AN/ABMRA, PLRZ, NEUP, and DYAI HeadlinesRecent News About These CompaniesPolyrizon (NASDAQ:PLRZ) Cut to "Sell" at Wall Street ZenMay 30, 2026 | americanbankingnews.comPolyrizon Appoints Veteran Entrepreneur Ami Oren to Board of DirectorsMay 27, 2026 | tipranks.comPolyrizon Stock Short Interest Report | NASDAQ:PLRZ | BenzingaMay 16, 2026 | benzinga.comPolyrizon Secures First U.S. Clinical Site for NASARIX Allergy Blocker TrialMay 13, 2026 | tipranks.comPolyrizon Ltd. Signs Clinical Trial Agreement for NASARIXTM Allergy Blocker Study in TexasMay 13, 2026 | quiverquant.comQPolyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical TrialMay 13, 2026 | globenewswire.comPulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable ProtectionMay 11, 2026 | prnewswire.comPolyrizon Expands U.S. Patent Claims for Intranasal Drug Delivery PlatformMay 4, 2026 | tipranks.comPolyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery PlatformMay 4, 2026 | globenewswire.comPolyrizon Ltd. Files Divisional Patent Application for Advanced Trap & Target Intranasal Drug Delivery TechnologyApril 27, 2026 | quiverquant.comQPolyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery PlatformApril 27, 2026 | globenewswire.comPLRZ Share News TodayApril 19, 2026 | uk.investing.comPolyrizon Raises $3.5 Million via Registered Direct Offering and Private PlacementApril 14, 2026 | theglobeandmail.comPolyrizon Ltd. Ordinary Shares (PLRZ) Institutional HoldingsApril 8, 2026 | nasdaq.comPolyrizon Ltd. Completes $3.5 Million Registered Direct Offering and Private PlacementApril 8, 2026 | quiverquant.comQPolyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private PlacementsApril 8, 2026 | globenewswire.comPolyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private PlacementApril 7, 2026 | finance.yahoo.comPolyrizon Ltd. Ordinary Shares (PLRZ) Option ChainMarch 29, 2026 | nasdaq.comPolyrizon Ltd. Ordinary Shares (PLRZ) Insider ActivityMarch 28, 2026 | nasdaq.comPolyrizon Ltd.: Polyrizon Provides 2025 and Recent HighlightsMarch 26, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 2026IonQ Just Posted a Breakout Quarter—But 1 Problem RemainsBy Nathan Reiff | May 7, 2026Before the Moon Base Gets Built, These 4 Companies WinBy Thomas Hughes | May 11, 2026Alphabet Just Unveiled Its Most Ambitious AI Lineup YetBy Ryan Hasson | May 26, 2026BMRA, PLRZ, NEUP, and DYAI Company DescriptionsBiomerica NASDAQ:BMRA$2.11 -0.07 (-3.21%) Closing price 03:59 PM EasternExtended Trading$2.12 +0.01 (+0.24%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.Dyadic International NASDAQ:DYAI$0.70 +0.01 (+1.64%) Closing price 04:00 PM EasternExtended Trading$0.70 -0.01 (-0.71%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.Neuphoria Therapeutics NASDAQ:NEUP$4.70 -0.19 (-3.89%) Closing price 04:00 PM EasternExtended Trading$4.70 0.00 (-0.11%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.Polyrizon NASDAQ:PLRZ$13.46 -0.63 (-4.47%) Closing price 04:00 PM EasternExtended Trading$13.58 +0.11 (+0.85%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coke's $10B India IPO Plan Pops the Top on Hidden Value Palo Alto Networks Accelerates Growth 31% on AI Demand Motorola's $1.5B Bet to Own the Skies Microsoft Build 2026 Is Really Just One Big AI Stress Test FedEx Unboxes Billions in Post-Spinoff Value Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter What IBM's $10-Billion Quantum Project Means For Smaller Players Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
